Simon J. Hogg

3.5k total citations · 1 hit paper
24 papers, 1.3k citations indexed

About

Simon J. Hogg is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Simon J. Hogg has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Hematology and 8 papers in Oncology. Recurrent topics in Simon J. Hogg's work include Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Simon J. Hogg is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Simon J. Hogg collaborates with scholars based in Australia, United States and France. Simon J. Hogg's co-authors include Ricky W. Johnstone, Paul A. Beavis, Mark A. Dawson, Stephin J. Vervoort, Phillip K. Darcy, Jake Shortt, Benjamin P. Martin, Leonie A. Cluse, Kristin Brown and James E. Bradner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Blood.

In The Last Decade

Simon J. Hogg

22 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the epigenetic regulation of antitumour immunity

2020 461 citations Simon J. Hogg, Paul A. Beavis et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon J. Hogg Australia	12	853	494	394	167	156	24	1.3k
Daniel Triner United States	11	593 0.7×	352 0.7×	212 0.5×	367 2.2×	81 0.5×	22	1.1k
Jing An United States	20	638 0.7×	600 1.2×	479 1.2×	73 0.4×	115 0.7×	61	1.2k
Maroof Alam United States	24	1.2k 1.4×	559 1.1×	364 0.9×	406 2.4×	83 0.5×	26	1.6k
Monique Smeets Australia	17	931 1.1×	455 0.9×	95 0.2×	195 1.2×	78 0.5×	31	1.3k
Pia Herrmann Germany	18	665 0.8×	443 0.9×	175 0.4×	236 1.4×	152 1.0×	31	1.1k
Pablo Matar Argentina	19	469 0.5×	673 1.4×	413 1.0×	177 1.1×	60 0.4×	37	1.3k
Fankai Meng China	19	612 0.7×	327 0.7×	112 0.3×	283 1.7×	111 0.7×	70	1.1k
Dominique Cathelin France	14	367 0.4×	591 1.2×	881 2.2×	104 0.6×	61 0.4×	17	1.4k
Jos de Graaf Germany	11	545 0.6×	666 1.3×	809 2.1×	170 1.0×	98 0.6×	14	1.4k
Miriam Redrado Spain	20	544 0.6×	518 1.0×	233 0.6×	270 1.6×	38 0.2×	39	1.1k

Countries citing papers authored by Simon J. Hogg

Since Specialization

Citations

This map shows the geographic impact of Simon J. Hogg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon J. Hogg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon J. Hogg more than expected).

Fields of papers citing papers by Simon J. Hogg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon J. Hogg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon J. Hogg. The network helps show where Simon J. Hogg may publish in the future.

Co-authorship network of co-authors of Simon J. Hogg

This figure shows the co-authorship network connecting the top 25 collaborators of Simon J. Hogg. A scholar is included among the top collaborators of Simon J. Hogg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon J. Hogg. Simon J. Hogg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scott, Kevin A., Hiroyuki Kojima, Nathalie Ropek, et al.. (2024). Covalent targeting of splicing in T cells. Cell chemical biology. 32(1). 201–218.e17. 5 indexed citations

Djajawi, Tirta M., Lizzy Pijpers, David Chisanga, et al.. (2024). PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity. Cell Reports. 43(3). 113831–113831. 13 indexed citations

Bewersdorf, Jan Philipp, Maximilian Stahl, Justin Taylor, et al.. (2023). E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 37(12). 2512–2516. 36 indexed citations

Ma, Xiao, Simon J. Hogg, Conor J. Kearney, et al.. (2023). Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma. Proceedings of the National Academy of Sciences. 120(36). e2306414120–e2306414120. 4 indexed citations

Witkowski, Matthew T., Soobeom Lee, Eric Wang, et al.. (2022). NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature Immunology. 23(10). 1424–1432. 26 indexed citations

So, Joan, Alexander C. Lewis, Lorey Smith, et al.. (2022). Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. EMBO Molecular Medicine. 14(7). e15203–e15203. 17 indexed citations

Bourcier, Jessie, Simon J. Hogg, Caroline Erickson, et al.. (2022). Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39. Blood. 140(Supplement 1). 1163–1164.

Hogg, Simon J., Conor J. Kearney, Imran G. House, et al.. (2022). Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer. Clinical Epigenetics. 14(1). 96–96. 3 indexed citations

Bjelosevic, Stefan, Andrea Newbold, Jennifer R. Devlin, et al.. (2021). Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia. Cancer Discovery. 11(6). 1582–1599. 50 indexed citations

10.

Kong, Isabella Y., Amanda Light, Izabela Todorovski, et al.. (2020). Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. Cell Reports. 33(3). 108290–108290. 5 indexed citations

11.

Hogg, Simon J., Paul A. Beavis, Mark A. Dawson, & Ricky W. Johnstone. (2020). Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery. 19(11). 776–800. 461 indexed citations breakdown →

12.

Shafik, Sarah H., Simon A. Cobbold, Manuel Llinás, et al.. (2020). The natural function of the malaria parasite’s chloroquine resistance transporter. Nature Communications. 11(1). 3922–3922. 55 indexed citations

13.

Costacurta, Matteo, Stephin J. Vervoort, Simon J. Hogg, et al.. (2020). Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Haematologica. 106(7). 2013–2017. 8 indexed citations

14.

Kearney, Conor J., Stephin J. Vervoort, Simon J. Hogg, et al.. (2018). Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology. 3(23). 254 indexed citations

15.

Hogg, Simon J., et al.. (2017). Clinical BET Inhibitor RG6146 Induces Intrinsic Apoptosis and Down-Regulates PD-L1 Expression and Induces Potent Anti-Tumor Activity in Models of Hematological Malignancy. Blood. 130. 2537–2537. 3 indexed citations

16.

Hogg, Simon J., Stephin J. Vervoort, Sumit Deswal, et al.. (2017). BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports. 18(9). 2162–2174. 238 indexed citations

17.

Hogg, Simon J., Andrea Newbold, Stephin J. Vervoort, et al.. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. 15(9). 2030–2041. 50 indexed citations

18.

West, Alison C., Benjamin P. Martin, Daniel M. Andrews, et al.. (2016). The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis. 5(4). e216–e216. 24 indexed citations

19.

Miller, Michelle S., Simon J. Mountford, Zhaohua Zheng, et al.. (2016). Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ. Bioorganic & Medicinal Chemistry Letters. 26(19). 4790–4794. 7 indexed citations

20.

Hogg, Simon J., John J. Evans, Peter Sykes, & Kenny Chitcholtan. (2015). A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. Journal of Ovarian Research. 8(1). 43–43. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact